Form 4: Ionis Pharmaceuticals Executive Receives Stock Options

Shannon L. Devers, EVP, Chief Human Resources Officer of Ionis Pharmaceuticals, was granted 11,280 Restricted Stock Units (RSUs) on October 15, 2024, according to a Form 4 filing.

Summary

• On October 15, 2024, Shannon L. Devers, the EVP, Chief Human Resources Officer at Ionis Pharmaceuticals, received a grant of 11,280 Restricted Stock Units (RSUs).
• These RSUs were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
• The RSUs vest in four equal annual installments.
• Upon vesting, the RSUs will be paid out in whole shares of Ionis common stock or cash as determined by the Company.
• Following this transaction, Devers directly owns 42,521 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The executive's compensation is tied to the performance of Ionis Pharmaceuticals' stock, incentivizing value creation.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to incentivize their executives.
• The specific number of RSUs granted and the vesting schedule are likely determined based on industry benchmarks, the executive's role and performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the executive to improve company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates